Comparing the current results to its competitors, Compugen Ltd reported Revenue increase in the 4 quarter 2025 by 161.14 % year on year. The sales growth was above Compugen Ltd's competitors' average revenue growth of 41.84 %, achieved in the same quarter.
Compugen Ltd's Comment on Competition and Industry Peers
The company competes with large pharmaceutical companies, specialty pharmaceutical and biopharmaceutical companies, biotech companies, academic institutions, government agencies, and other private and public research organizations. Notable competitors include AstraZeneca, which is developing rilvegostomig, and Memorial Sloan Kettering Cancer Center, which is conducting a Phase 1 trial for relapsed/refractory AML with CD371-YSNVZ-IL18. Competition extends to securing clinical sites, clinician participation, and patient enrollment in clinical trials. Competitors may possess greater resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing, and may develop products targeting similar mechanisms, drug targets, pathways, or therapeutic indications.
Anika Therapeutics Inc is a medical technology company that focuses on developing and commercializing therapeutic products to treat tissue-related disorders. Their business model revolves around conducting extensive research and development to create innovative therapies, partnering with healthcare professionals and distributors to bring their products to market, and generating revenue through the sale of these products worldwide. They also collaborate with other companies and academic institutions to enhance their product portfolio and expand their reach in the healthcare industry.
Tango Therapeutics Inc is a biotechnology company that focuses on developing cancer therapies using DNA sequencing and computational biology. Their business model revolves around discovering and developing precision medicines by leveraging their expertise in genomics and biology to target specific cancer vulnerabilities.
Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.
Schrodinger Inc is a computational drug discovery company that utilizes physics-based solutions to accelerate the discovery and development of new drugs. Their business model involves providing software and services to pharmaceutical and biotechnology companies, enabling them to optimize and streamline their drug discovery processes. By leveraging their unique expertise in computational chemistry and molecular modeling, Schrodinger aims to empower their clients in the pursuit of efficient and effective drug development.
Sources:
Compugen Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Compugen Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
